Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Vit K Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD prof., Andrea Janikova, MD PhD, Assoc Prof, David Belada, Tomas Kozak, MD, PhD, Prof., David Salek, MD PhD, Alice Sykorova, MD PhD, Heidi Mocikova, MD, PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trneny

Blood (2016) 128 (22): 1779.

https://doi.org/10.1182/blood.V128.22.1779.1779

Published: 2016

Journal Articles

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Heidi Mocikova, MD, PhD, Jana Markova, MD, Lubica Gaherova, MD, Lukas Smolej, MD, PhD, Assoc.Prof., Martin Simkovic, MD, Tomas Kozak, MD, PhD, Prof.

Blood (2015) 126 (23): 5298.

https://doi.org/10.1182/blood.V126.23.5298.5298

Published: 2015

Journal Articles

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Heidi Mocikova, MD, PhD, Magdalena Klanova, MD, Martin Spacek, MD, PhD, Robert Pytlik, MD, PhD, Tomas Kozak, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof., Vit Pospisil, PhD

Blood (2014) 124 (21): 5412.

https://doi.org/10.1182/blood.V124.21.5412.5412

Published: 2014

Journal Articles

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Dominik Selleslag, Ann Janssens, Hans Wadenvik, Michael Steurer, MD, Philippe Quittet, MD, Georgia Kaiafa, Tomas Kozak, MD, Helen Papadaki, Jean-François Viallard, MD, PhD, Kerry Dillingham, Georg Kreuzbauer, MD

Blood (2012) 120 (21): 3316.

https://doi.org/10.1182/blood.V120.21.3316.3316

Published: 2012

Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2011) 118 (21): 290.

https://doi.org/10.1182/blood.V118.21.290.290

Published: 2011

Journal Articles

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Vit Pospisil, Heidi Mocikova, MD, PhD, Milada Jankovska, MD, Jana Markova, MD, Lubica Gaherova, MD, Tomas Kozak, MD, PhD, Tomas Stopka, MD, PhD

Blood (2011) 118 (21): 3663.

https://doi.org/10.1182/blood.V118.21.3663.3663

Published: 2011

Journal Articles

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Ann Janssens, MD, Michael D. Tarantino, MD, Robert Bird, MD, Maria Gabriella Mazzucconi, MD, Ralph Vincent V. Boccia, MD, Maria Fernanda Lopez-Fernandez, MD, Tomas Kozak, MD, Michael Steurer, MD, Peter A.W. Te Boekhorst, MD, PhD, Kerry Dillingham, MSc, Richard Lizambri, MD

Blood (2011) 118 (21): 3279.

https://doi.org/10.1182/blood.V118.21.3279.3279

Published: 2011

Journal Articles

Identification of Novel Molecular Markers for the Follow-up of Minimal Residual Disease in Hematooncological Disorders

David Warren Hardekopf, Tereza Jancuskova, Marie Jarosova, Lucie Krutilkova, Radek Plachy, Lenka Zejskova, Radek Cmejla, PhD, Jan Vydra, Tomas Kozak, MD, PhD, Michal Karas, Vladimir Koza, MD, Alzbeta Zavrelova, MD, Pavel Zak, MD, PhD, Lukas Smolej, M.D., Ph.D., Sona Pekova

Blood (2011) 118 (21): 4905.

https://doi.org/10.1182/blood.V118.21.4905.4905

Published: 2011

Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Blood (2008) 112 (11): 328.

https://doi.org/10.1182/blood.V112.11.328.328

Published: 2008

Journal Articles

Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro

Sona Pekova, M.D., PhD., Radek Cmejla, PhD, Tomas Kozak, MD, PhD, Lukas Smolej, MD, PhD, Martin Spacek, MD., Miroslav Prucha, MD., PhD., Ondrej Hrusak

Blood (2008) 112 (11): 3795.

https://doi.org/10.1182/blood.V112.11.3795.3795

Published: 2008

Journal Articles

Molecular Variability of FLT3/ITD Mutants and Their Impact on the Differentiation Program of 32D Cells: Implications for the Biological Properties of AML Blasts

Sona Pekova, M.D., PhD., Michal Dvorak, PhD., Robert Ivanek, Sabrina Rueggeberg, Stefan Leicht, Tomas Kozak, MD, PhD, Jiri Vrba, MD., Jiri Schwarz, MD., PHD., Petr Cetkovsky, MD., PHD., Miroslav Prucha, MD., PHD., Ondrej Hrusak

Blood (2008) 112 (11): 4480.

https://doi.org/10.1182/blood.V112.11.4480.4480

Published: 2008

Journal Articles

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Mauricette Michallet, MD, PhD, Quoc Hung Le, MD, Peter Dreger, Mohamad Sobh, PhD, Dietger Niederwieser, MD, Vladimir Koza, MD, Tapani Ruutu, Nigel H. Russell, MD, Leo Verdonck, Donald Milligan, MD, MBChB, Nathalie Dhedin, Tomas Kozak, MD, PhD, Marc Boogaerts, MD, PhD, Juergen Finke, Nathalie Tedone, Anja Van Biezen, Ronald Brand, Theo de Witte on behalfhe European Group for Blood Marrow Transplantation

Blood (2008) 112 (11): 566.

https://doi.org/10.1182/blood.V112.11.566.566

Published: 2008

Journal Articles

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Marek Trneny, MD, David Belada, MD, Ingrid Vasova, MD, Robert Pytlik, MD, Tomas Kozak, MD, Alice Sykorova, MD, Katerina Kubackova, MD, Jan Pirnos, MD, Ingrid Bolomska, MD, Marketa Petrova, Ing

Blood (2005) 106 (11): 2444.

https://doi.org/10.1182/blood.V106.11.2444.2444

Published: 2005

NARROW

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Identification of Novel Molecular Markers for the Follow-up of Minimal Residual Disease in Hematooncological Disorders

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro

Molecular Variability of FLT3/ITD Mutants and Their Impact on the Differentiation Program of 32D Cells: Implications for the Biological Properties of AML Blasts

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only